MEK-话题@MedSci

#MEK#

68篇内容 | 2185人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1943876, encodeId=169819438e6a1, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=Cell Metabolism：炎症、肥胖和胰岛素抵抗间关联新信号NBR1/MEKK3, objectType=article, longId=38101, objectId=05d238101f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=05d238101f4, replyNumber=0, likeNumber=74, createdTime=2014-08-15, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=05d238101f4, moduleTitle=Cell Metabolism：炎症、肥胖和胰岛素抵抗间关联新信号NBR1/MEKK3, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=05d238101f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943875, encodeId=935419438e554, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=Cell Metabolism：阻断NBR1-MEKK3信号或可预防2型糖尿病, objectType=article, longId=38096, objectId=29eb380967d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29eb380967d, replyNumber=0, likeNumber=63, createdTime=2015-03-19, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29eb380967d, moduleTitle=Cell Metabolism：阻断NBR1-MEKK3信号或可预防2型糖尿病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=29eb380967d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943873, encodeId=195d19438e3aa, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=CHMP建议批准GSK黑色素瘤药物Mekinist, objectType=article, longId=34601, objectId=a90134601e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a90134601e7, replyNumber=0, likeNumber=68, createdTime=2014-05-21, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a90134601e7, moduleTitle=CHMP建议批准GSK黑色素瘤药物Mekinist, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a90134601e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943874, encodeId=c20719438e49e, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=GSK皮肤癌药物Mekinist获欧盟批准, objectType=article, longId=37783, objectId=98b53e783a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=98b53e783a8, replyNumber=0, likeNumber=69, createdTime=2015-06-28, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=98b53e783a8, moduleTitle=GSK皮肤癌药物Mekinist获欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=98b53e783a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943877, encodeId=e1a319438e75e, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=黑色素瘤Mekinist+Tafinlar组合疗法III期研究疗效显著提前终止（COMBI-v试验）, objectType=article, longId=38153, objectId=7ace381535b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7ace381535b, replyNumber=0, likeNumber=67, createdTime=2014-09-17, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7ace381535b, moduleTitle=黑色素瘤Mekinist+Tafinlar组合疗法III期研究疗效显著提前终止（COMBI-v试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7ace381535b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943871, encodeId=ef0019438e18b, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=Curr Biol：Ras→BRAF→MEK→ERK细胞信号有助于对黑色素瘤的治疗, objectType=article, longId=6258, objectId=066b625857, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=066b625857, replyNumber=0, likeNumber=89, createdTime=2012-08-07, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=066b625857, moduleTitle=Curr Biol：Ras→BRAF→MEK→ERK细胞信号有助于对黑色素瘤的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=066b625857)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943872, encodeId=adfb19438e2a3, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=Lancet ：MEK抑制剂Trametinib的Ⅱ期临床试验推荐剂量确定, objectType=article, longId=8271, objectId=29cd82e153, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29cd82e153, replyNumber=0, likeNumber=78, createdTime=2012-08-16, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29cd82e153, moduleTitle=Lancet ：MEK抑制剂Trametinib的Ⅱ期临床试验推荐剂量确定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=29cd82e153)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943870, encodeId=7bbe19438e05d, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=BJC：联合使用ALK和MEK抑制剂治疗非小细胞肺癌, objectType=article, longId=4106, objectId=c962410668, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c962410668, replyNumber=0, likeNumber=81, createdTime=2012-12-04, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c962410668, moduleTitle=BJC：联合使用ALK和MEK抑制剂治疗非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c962410668)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

MEK

2020-05-29

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

Cell Metabolism：炎症、肥胖和胰岛素抵抗间关联新信号NBR1/MEKK3

2014-08-15

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

Cell Metabolism：阻断NBR1-MEKK3信号或可预防2型糖尿病

2015-03-19

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

CHMP建议批准GSK黑色素瘤药物Mekinist

2014-05-21

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

GSK皮肤癌药物Mekinist获欧盟批准

2015-06-28

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

黑色素瘤Mekinist+Tafinlar组合疗法III期研究疗效显著提前终止（COMBI-v试验）

2014-09-17

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

Curr Biol：Ras→BRAF→MEK→ERK细胞信号有助于对黑色素瘤的治疗

2012-08-07

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

Lancet ：MEK抑制剂Trametinib的Ⅱ期临床试验推荐剂量确定

2012-08-16

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

BJC：联合使用ALK和MEK抑制剂治疗非小细胞肺癌

2012-12-04

科室
- - 订阅+
  - 更多科室
工具
服务